Evidence map›Paper›PMID 42141340›Full record

ReviewAnnals of surgical oncology2026

Biomarker-Driven Management of Nonmetastatic GEJ Adenocarcinoma.

Hideo Takahashi, Ahmed Dehal, Haejin In, Steve Kwon, Mariam Eskander, Roberto J Vidri, Brett L Ecker, Erin Ward, Prejesh Philips, Ioannis T Konstantinidis and 8 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hideo TakahashiDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, USA.
Ahmed DehalDepartmemt of Surgery, Southern California Permanente Medical Group, Department of Clinical Sciences, Kaiser Permanente School of Medicine, Los Angeles, CA, USA.
Haejin InDivision of Surgical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Steve KwonDepartment of Surgery, Boston University School of Medicine, Boston, MA, USA.
Mariam EskanderDivision of Surgical Oncology, Rutgers Cancer Institute, New Brunswick, NJ, USA.
Roberto J VidriDepartment of Surgery, Division of Surgical Oncology and Endocrine Surgery, University of North Carolina, Chapel Hill, NC, USA.
Brett L EckerDepartment of Surgery, Northwestern University, Chicago, IL, USA.
Erin WardDepartment of Surgery, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Prejesh PhilipsDivision of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY, USA.
Ioannis T KonstantinidisDepartment of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Nasreen VohraDivision of Surgical Oncology, ECU Health, Greenville, NC, USA.
Brian KaplanDepartment of Surgery, NYU Langone Health, New York, NY, USA.
Geoffrey NunnsDivision of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Jeremy DavisDivision of Surgical Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Travis E GrotzDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
Richelle WilliamsDivision of Surgical Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Moshim KukarDepartment of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Streets, Buffalo, NY, USA. Moshim.Kukar@roswellpark.org.
Society of Surgical Oncology (SSO) Gastrointestinal (GI) Disease Site Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvances in understanding the molecular landscape of gastroesophageal junction (GEJ) adenocarcinoma underscore the need for biomarker-driven treatment approaches. MATERIALS AND

methodsThe Society of Surgical Oncology (SSO) Gastrointestinal (GI) Disease Site Working Group has developed practice guidelines for the biomarker-based management of nonmetastatic GEJ adenocarcinoma, with specific integration of microsatellite instability (MSI) status.

resultsAlthough multimodal therapy has improved outcomes, treatment strategies for GEJ adenocarcinoma remain largely stage-based rather than biomarker-directed. With emerging evidence supporting the prognostic and predictive roles of MSI-high (MSI-H), human epidermal growth factor receptor 2 (HER2), and other novel targets, there is an urgent need for clear guidance on how to incorporate biomarkers into the management of resectable disease.

conclusionsThese guidelines provide evidence-based recommendations to support precision oncology in GEJ cancer care.

Indexed as

AdenocarcinomaBiomarkers, TumorEsophageal NeoplasmsEsophagogastric JunctionMicrosatellite InstabilityPractice Guidelines as TopicStomach NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansPrognosisBiomarkers, TumorErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID42141340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.